← Eichor
Study identifier: NCT06466018 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Research Into Diagnostic and Prognostic Molecular and Imaging Biomarkers of Ocular Disorders Associated With Neurovascular Deregulation: Biocor Cohort

Condition: Ocular Rosacea · Pachychoroid Disease  ·  Sponsor: Clinact

PhaseNA
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

BIOCOR is an interventional clinical trial whose main objectives are Objectif are identify molecular biomarker(s) of ocular rosacea and pachychoroid. Endpoints are : Correlation between pachychoroidosis (defined by choroidal phenotype parameters in OCT and autofluorescence) or the stage of ocular rosacea (ROSCO(29) definition) and biological markers selected on the basis of preclinical work (animal model) and by unbiased methods (proteomics, metabolomics, meibum lipidomics). The study of circulating, ocular and functional biomarkers would enable us to confirm our hypothesis and identify patients who could benefit from treatments that regulate the ANS and/or mineralocorticoid pathways.

This description comes directly from the study's public registry record.

Talk to the study team

CRA  ·  + 3315 841 28 98  ·  contact@multihealthgroup.com

Always discuss trial participation with your own doctor first.

Locations (1)

Departement of Ophthalmology, COCHIN HospitalParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06466018